THREAD, in partnership with trial intelligent specialist Lokavant, has released the results of a joint analysis comparing decentralized trial performance during the ongoing COVID-19 pandemic to traditional, on-site studies. According to the report, decentralized research approaches are performing better than traditional trials when it comes to aspects like patient recruitment and retention levels.
The study indicates both patient recruitment and retention dropped industry-wide in early 2020, thanks to the COVID-19 pandemic causing global quarantines and stay-at-home orders. Interestingly, according to the findings, decentralized trials were able to more quickly bounce back to pre-pandemic levels, while traditional-design trials were still struggling to recover through September.
Report authors posit that trials using decentralized technology like THREAD’s platform were able to recover quickly because they already had in place, or were in a position to readily add, remote features and services. Additionally, trials with decentralized features had the ability to pivot more readily when their geographical areas were hit with shutdowns.
By contrast, the study indicates, traditional-design trials were slower to recover. Report authors shared that traditional trials had difficulty recovering because their protocols, technologies, and schedules precluded adoption of decentralized approaches.
John Reites, THREAD CEO, said the findings of the study indicate decentralized trials can be more flexible, resilient, and adaptable to current challenges.
"traditional" - Google News
February 16, 2021 at 07:41PM
https://ift.tt/3b8NcSB
Decentralized trials more pandemic-proof than traditional: study - OutSourcing-Pharma.com
"traditional" - Google News
https://ift.tt/36u1SIt
Shoes Man Tutorial
Pos News Update
Meme Update
Korean Entertainment News
Japan News Update
Bagikan Berita Ini
0 Response to "Decentralized trials more pandemic-proof than traditional: study - OutSourcing-Pharma.com"
Post a Comment